Objectives: Pancreatic cancer is the fourth most common cause of cancer deaths in the USA. Despite the fact that the radiotherapy in addition to chemotherapy (CT) is frequently employed, the role of chemoradiation therapy (CRT) in the treatment of locally advanced pancreatic cancer (LAPC) remains controversial. We conducted a systemic review and meta-analysis to evaluate the effect of radiation treatment in addition to CT in patients with LAPC.

Methods: Only randomized controlled trials that compared CRT to CT and reported time to event summary were included in this study. The primary end point was overall survival expressed as hazard ratio (HR). Due to significant heterogeneity, random-effects model statistics were used.

Results: Five eligible studies were included with a total of 593 patients (CT, N = 298; CRT, N = 295). Two studies demonstrated statistically significant difference in OS in favor of CRT and the rest of the studies did not demonstrate any significant differences. Meta-analysis demonstrated that there was a non-significant trend toward a survival benefit in the CRT arm; HR 0.913 (95 % CI 0.595-1.400, p = 0.675). No significant differences in overall results were seen with sensitivity analysis.

Conclusions: The addition of radiation therapy to CT in the treatment of LAPC is associated with a non-significant trend toward survival advantage. Larger randomized controlled trials using modern CT regimens and radiation techniques are needed to further clarify the role of radiation in this setting.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12029-015-9734-zDOI Listing

Publication Analysis

Top Keywords

pancreatic cancer
12
chemoradiation therapy
8
locally advanced
8
advanced pancreatic
8
randomized controlled
8
controlled trials
8
non-significant trend
8
trend survival
8
crt
5
meta-analysis randomized
4

Similar Publications

Objective: To investigate the clinicopathological features and long-term outcomes of cystic and solid pancreatic neuroendocrine tumors (PanNETs).

Summary Background Data: PanNETs uncommonly present as cystic lesions. Whether cystic PanNETs represent a distinct clinical entity compared to solid PanNETs is controversial.

View Article and Find Full Text PDF

Background: Pancreatic cancer is a highly malignant tumor with a poor prognosis, and current treatment methods have limited effectiveness. Therefore, developing new and more effective therapeutic strategies is crucial. This study aims to establish pH-responsive silk fibroin (SF) nanoparticles encapsulating β-hydroxyisovalerylshikonin (SF@β-HIVS) to enhance the therapeutic effects against pancreatic cancer.

View Article and Find Full Text PDF

Multiparametric MRI for Assessment of the Biological Invasiveness and Prognosis of Pancreatic Ductal Adenocarcinoma in the Era of Artificial Intelligence.

J Magn Reson Imaging

January 2025

Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology, Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, China.

Pancreatic ductal adenocarcinoma (PDAC) is the deadliest malignant tumor, with a grim 5-year overall survival rate of about 12%. As its incidence and mortality rates rise, it is likely to become the second-leading cause of cancer-related death. The radiological assessment determined the stage and management of PDAC.

View Article and Find Full Text PDF

The underlying mechanisms between cancer stem cells (CSC) and epithelial-mesenchymal transition (EMT) in pancreatic cancer (PC) remain unclear. In this study, we identified TGIF2 as a target gene of CSC using sncRNA and machine learning. TGIF2 is closely related to the expression of SOX2, EGFR, and E-cadherin, indicating poor prognosis.

View Article and Find Full Text PDF

Treatment with pegylated nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (folinic acid; 5-FU/LV) has demonstrated remarkable efficacy for metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical trials. However, real-world data on the effectiveness of nal-IRI+5-FU/LV is heterogeneous and is lacking in Spain. To assess the effectiveness and safety of nal-IRI+5-FU/LV in real-life PDAC patients in Spain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!